Kate Inman - VBI Vaccines Director
| VBIV Stock | USD 0.63 0.02 3.28% |
Director
Kate Inman is Director of VBI Vaccines since 2015.
| Tenure | 9 years |
| Address | 160 Second Street, Cambridge, MA, United States, 02142 |
| Phone | 617 830 3031 |
| Web | https://www.vbivaccines.com |
VBI Vaccines Management Efficiency
The company has return on total asset (ROA) of (0.295) % which means that it has lost $0.295 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1979) %, meaning that it created substantial loss on money invested by shareholders. VBI Vaccines' management efficiency ratios could be used to measure how well VBI Vaccines manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -1.79 in 2024. Return On Capital Employed is likely to climb to -6.77 in 2024. At this time, VBI Vaccines' Other Current Assets are fairly stable compared to the past year. Other Assets is likely to climb to about 1.6 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 42.9 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Richard Markham | Vaxart Inc | 65 | |
| Stuart Davidson | Tonix Pharmaceuticals Holding | 59 | |
| Randal Chase | GeoVax Labs | 67 | |
| John McKey | Ibio Inc | 74 | |
| Jeffrey Johnson | Jaguar Animal Health | 45 | |
| Deborah Messemer | Allogene Therapeutics | 60 | |
| John Micek | Jaguar Animal Health | 64 | |
| Gordon Ringold | Ardelyx | 66 | |
| Paul Strickland | Annovis BioInc | 37 | |
| Robert Bazemore | Ardelyx | 50 | |
| Ari Azhir | Jaguar Animal Health | 69 | |
| Michael Dunne | Vaxart Inc | 56 | |
| Yiquan Song | Annovis BioInc | 45 | |
| Daniel Goodman | Tonix Pharmaceuticals Holding | 56 | |
| Samuel Saks | Tonix Pharmaceuticals Holding | 62 | |
| John Richard | Vaxart Inc | 58 | |
| Owen Witte | Allogene Therapeutics | 68 | |
| Bruce Daugherty | Tonix Pharmaceuticals Holding | 56 | |
| Geoffrey Block | Ardelyx | N/A | |
| Lorin Randall | Aurinia Pharmaceuticals | 74 | |
| David MacNaughtan | Jaguar Animal Health | 50 | |
Management Performance
| Return On Equity | -2.2 | ||||
| Return On Asset | -0.29 |
VBI Vaccines Leadership Team
Elected by the shareholders, the VBI Vaccines' board of directors comprises two types of representatives: VBI Vaccines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VBI. The board's role is to monitor VBI Vaccines' management team and ensure that shareholders' interests are well served. VBI Vaccines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VBI Vaccines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Adam Buckley, Vice President - Operations and Project Management | ||
| Nicole Anderson, Director Relations | ||
| David Anderson, Chief Scientific Officer | ||
| Trent Davis, Director | ||
| Shayla Forster, Corporate Secretary | ||
| Joanne Cordeiro, Director | ||
| Sam Chawla, Director | ||
| Alan Timmins, Independent Director | ||
| Avi Mazaltov, Global SciVac | ||
| Misha Nossov, Senior Europe | ||
| Marc Kirchmeier, VP of Formulations | ||
| Curtis Lockshin, CEO, Director | ||
| David Rector, Additional Independent Director | ||
| Dmitry Genkin, Director | ||
| Michel Wilde, Independent Director | ||
| Kate Inman, Director | ||
| Ran Nussbaum, Director | ||
| FRCPC MD, Chief Officer | ||
| Tomer Kariv, Director | ||
| Adam Logal, Director | ||
| Steven Gillis, Independent Chairman of the Board | ||
| Steven Rubin, Chairman of the Board | ||
| Jeff Baxter, CEO, Director | ||
| Nell Beattie, Chief Officer | ||
| Athena Kartsaklis, Principal Financial and Accounting Officer, Senior Vice President - Finance, Chief Compliance Officer, Corporate Controller | ||
| James Martin, CFO | ||
| FCMA FCMA, CEO Pres | ||
| Christopher McNulty, CFO and Head of Business Development | ||
| Jeffery FCMA, CEO President | ||
| Scott Requadt, Independent Director | ||
| Egidio Nascimento, CFO | ||
| John Dillman, Chief Officer |
VBI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is VBI Vaccines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.2 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (0.98) % | ||||
| Current Valuation | 31 M | ||||
| Shares Outstanding | 28.43 M | ||||
| Shares Owned By Insiders | 7.69 % | ||||
| Shares Owned By Institutions | 11.84 % | ||||
| Number Of Shares Shorted | 289.12 K | ||||
| Price To Earning | (3.79) X | ||||
| Price To Book | 0.82 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether VBI Vaccines is a strong investment it is important to analyze VBI Vaccines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact VBI Vaccines' future performance. For an informed investment choice regarding VBI Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for VBI Stock analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.79) | Revenue Per Share 0.689 | Quarterly Revenue Growth 19.896 | Return On Assets (0.29) | Return On Equity (2.20) |
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.